Tiny study hopes to unlock muscle secrets in overweight men

NCT ID NCT07421024

Not yet recruiting Knowledge-focused Sponsor: Morten Hostrup, PhD Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will give 10 overweight men a daily pill called ATR-258 for 8 weeks to see how it changes signaling pathways in their muscles. Researchers will take small muscle samples and measure blood sugar control and body composition. The goal is to understand the biology, not to treat or cure obesity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATR-258 (a drug that targets beta-2 receptors in muscle)
What this could lead to: If successful, this study could reveal new ways to improve muscle metabolism and glucose handling in people with overweight or obesity.
What could go wrong: This is a small, early-phase mechanistic study with only 10 participants. It is designed to understand biology, not to test a treatment, so results may not lead to any direct health benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Locations

University of Copenhagen, August Krogh Section for Human & Molecular Physiology

Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.